Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
주식 순위 #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
주가
$0.01292666
마지막 동기화: 2025-04-08
시가총액
$157.54K
변동 (1일)
6.84%
변동 (1년)
0.00%
국가
GB
거래 Synairgen plc (SNG)

카테고리

Synairgen plc (SNG)의 수익
Jun 2024 기준 수익 TTM: $-4.64M
Synairgen plc의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-4.64M입니다. 2022년에 회사는 $-24.31M의 수익을 올렸으며 이는 2021년의 수익 $-78.22M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Synairgen plc의 수익 기록 (2004 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-4.64M -62.26%
2023 $-12.29M -49.43%
2022 $-24.31M -68.92%
2021 $-78.22M 222.66%
2020 $-24.24M 281.43%
2019 $-6.36M 121,729.64%
2018 $-5.22K -336.99%
2017 $2.20K -100.05%
2016 $-4.20M 111,307.18%
2015 $-3.77K -315.15%
2014 $1.75K -100.05%
2013 $-3.75M -6.03%
2012 $-4.00M -32.03%
2011 $-5.88M 34.57%
2010 $-4.37M -6.90%
2009 $-4.69M -4.50%
2008 $-4.91M 29.79%
2007 $-3.78M 57.39%
2006 $-2.40M 119.97%
2005 $-1.09M 293.81%
2004 $-277.59K 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.27B -113,800.85%
US
$1.95B -42,146.41%
NL
- -
CH
- -
KR
$3.01B -64,888.45%
BE